机构：[1]Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China.[2]Department of Dermatology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, People's Republic of China.[3]Department of Medical Oncology, Senior Ward and Phase I Clinical Trial Ward, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610000, Sichuan, People's Republic of China.四川省人民医院四川省肿瘤医院
This study is supported by the National Natural Science Foundation of China
(No. 81661168011, 82003196, and 82270198), the Cancer Innovative Research
Program of Sun Yat-sen University Cancer Center (No. CIRP-SYSUCC-0022), the
Outstanding Young Scientific and Technological Talents Fund of Sichuan Province
(No. 2022JDJQ0059), and Medical Science and Technology Foundation of
Guangdong Province (No. A2021426).
第一作者机构：[1]Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China.[3]Department of Medical Oncology, Senior Ward and Phase I Clinical Trial Ward, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610000, Sichuan, People's Republic of China.
推荐引用方式(GB/T 7714)：
Huang Huageng,Deng Xinyi,Yu Le,et al.EZH1/2 alteration as a potential biomarker for immune checkpoint inhibitors across multiple cancer types[J].JOURNAL OF TRANSLATIONAL MEDICINE.2023,21(1):doi:10.1186/s12967-023-04759-3.
APA：
Huang Huageng,Deng Xinyi,Yu Le,Huang He,Wang Zhao...&Lin Tongyu.(2023).EZH1/2 alteration as a potential biomarker for immune checkpoint inhibitors across multiple cancer types.JOURNAL OF TRANSLATIONAL MEDICINE,21,(1)
MLA：
Huang Huageng,et al."EZH1/2 alteration as a potential biomarker for immune checkpoint inhibitors across multiple cancer types".JOURNAL OF TRANSLATIONAL MEDICINE 21..1(2023)
医学